ARTICLE | Regulation
GSK extends competitive edge in RSV with first vaccine approval
FDA approves Arexvy as first RSV vaccine for older adults, now GSK needs to drive demand
May 3, 2023 9:50 PM UTC
The first approval of a respiratory syncytial virus vaccine marks a major scientific breakthrough for a problem researchers have been trying to solve for decades. It’s also an important win for GlaxoSmithKline, which has seen vaccines become a bright spot in its clinical and commercial strategies.
Though GSK plc (LSE:GSK; NYSE:GSK) won the race to the market, beating out competitors including Pfizer Inc. (NYSE:PFS), its next challenge may be driving up demand in a population with low awareness of the threat that RSV poses. ...